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Abstract K-CEHC (2,5,7,8-tetramethyl-2(2P-carboxyethyl)-6-
hydroxychroman) is a urinary vitamin E metabolite with a
truncated phytyl tail. To test whether natural and synthetic
vitamin E are similarly converted to K-CEHC, 6 humans
consumed 150 mg each RRR-K-[5-(C2H3)]- and all rac-K-
[5,7(C2H3)2]-tocopheryl acetates (d3RRR-K- and d6all rac-K-
tocopheryl acetates, respectively). Plasma was collected at 0, 6,
12 and 24 h; urine (24 h) at 0, 1, 2, 3, 4 and 8 days. Following
dosing, plasma was enriched with d3RRR-K-tocopherol, while
urine was enriched with K-CEHC derived from d6all rac-K-
tocopherol. Thus, synthetic compared with natural vitamin E is
preferentially metabolized to K-CEHC and excreted.
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1. Introduction
Vitamin E is not just one molecule, but rather there are
eight di¡erent, naturally occurring forms of vitamin E: K-,
L-, Q-, and N-tocopherols and K-, L-, Q-, and N-tocotrienols;
yet only K-tocopherol has high biological activity [1]. Vitamin
E is unique because the chemically synthesized form is not
identical to the naturally occurring form, RRR-K-tocopherol.
The synthesized form has eight di¡erent stereoisomers and is
labeled all rac-K-tocopherol. Historically, the rat fetal resorp-
tion assay was used to assess the biological activity of natu-
rally occurring non-K-tocopherol vitamin E forms [2]. The use
of deuterated tocopherols and the use of chiral columns to
examine vitamin E stereoisomers in plasma and tissues [3,4],
as well as the isolation and cloning of the K-tocopherol trans-
fer protein to allow direct determination of its binding proper-
ties [5] have con¢rmed that plasma contains few or no 2S-K-
tocopherol isomers, and that the K-tocopherol transfer protein
(K-TTP) does not bind them. Commercially available vitamin
E supplements can contain either the natural (RRR-K-toco-
pherol) or the synthetic form (all rac-K-tocopherol).
The biological activity of vitamin E has been suggested to
be dependent upon the function of K-TTP [5]. However, vita-
min E metabolism may also have an important role in this
regard. Vitamin E metabolites in human urine include both
the metabolite of K-tocopherol (2,5,7,8-tetramethyl-2(2P-car-
boxyethyl)-6-hydroxychroman, K-CEHC) [6,7] and that of
Q-tocopherol (2,7,8-trimethyl-2-(2P-carboxyethyl)-6-hydroxy-
chroman, Q-CEHC or LLUK) [8,9]. These metabolites result
from degradation of the phytyl tail ; they are not oxidation
products of vitamin E. It is unknown where the metabolites
are synthesized, but the central role of the liver in discrimi-
nating between vitamin E forms suggests that the liver may be
the site of vitamin E metabolism. Previously, K-CEHC was
found excreted in the urine only in response to daily vitamin E
supplementation with at least 50^150 mg K-tocopherol [6].
However, improvements in the detection limit of K-CEHC
excretion have allowed its measurement in the urine of non-
vitamin E supplemented individuals (A. Elsner, M. Schultz, J.
Brueckner, M.G. Traber, R. Brigelius-FloheŁ, unpublished).
These studies revealed K- CEHC as a normal vitamin E me-
tabolite constitutively present in human urine at low concen-
trations and it was probably dependent on vitamin E intake.
The relationship between plasma vitamin E and urinary
metabolites is unclear. K-CEHC increases in the urine with
increasing plasma K-tocopherol concentrations re£ecting in-
creasing amounts of vitamin E supplementation [6]. It is un-
known what happens to Q-CEHC. Conversion of all rac-K-
tocopherol to the vitamin E metabolite, K-CEHC, may be
increased compared with the conversion of RRR-K-tocopherol
because less all rac-K-tocopherol is exported into plasma [10].
To test this hypothesis, we have used a single dose of two
forms of vitamin E labeled with di¡erent amounts of deute-
rium to assess whether the natural and synthetic forms of
vitamin E are similarly converted to K-CEHC.
2. Methods
2.1. Deuterated vitamin E
RRR-K-5-(C2H3)Tocopheryl acetate and all rac-K-5,7-
(C2H3)2tocopheryl acetate (d3RRR-K- and d6all rac-K-tocopheryl ace-
tates, respectively) were a gift from the Natural Source Vitamin E
Association (NSVEA) and were synthesized by Eastman Kodak, Ro-
chester, NY, USA. The compounds were determined to be 96% RRR-
and 93% all rac-K-tocopheryl acetate by weight. Their isotopic purities
at their nominal level of deuteration were 84% (d0 : 4.0%; d1 : 2.0%;
d2 : 9.7%) and 86% (d0, d1 : 6 0.1%; d2 : 0.1%; d3 : 0.8%; d4 : 1.3%;
d5 : 11.2%), respectively. The d3-RRR- and d6-all rac-K-tocopheryl
acetates were encapsulated in gelatin capsules as 1:1 mixtures in
150-mg quantities diluted in K-tocopherol stripped corn oil. The
RRR/all rac ratio was determined by GC-MS to be 0.98.
2.2. K-CEHC and Q-CEHC
K-CEHC (2,5,7,8-tetramethyl-2(2P-carboxyethyl)-6-hydroxychro-
man) was synthesized by Laborat, Berlin, Germany. Q-CEHC (2,7,8-
trimethyl-2(2P-carboxyethyl)-6-hydroxychroman, LLUK) was a kind
gift from W.J. Wechter (Laboratory of Chemical Endocrinology,
Loma Linda University School of Medicine, Loma Linda, CA, USA).
2.3. Study design
The study was approved by the local (Brandenberg, Germany) Re-
search Ethics Committee in accordance with the Helsinki Declaration
and by the human subjects committee of the University of California,
Davis, CA, USA. The study was carried out at the German Institute
of Human Nutrition using 6 normolipidemic adult volunteers aged
27^52 years, one male and 5 female subjects, who gave written in-
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formed consent. They consumed a single dose of encapsulated 150-mg
d3-RRR- and 150-mg d6-all rac-K-tocopheryl acetates (8:00 a.m.).
Blood samples from non-fasting volunteers were taken prior to sup-
plementation and at 6, 12 and 24 h. 24-h urine was collected (from
7:00 to 7:00 a.m.) a day prior to supplementation, and 1, 2, 3, 4 and 8
days after supplementation.
2.4. Extraction of plasma vitamin E and measurement of
non-deuterated and deuterated K-tocopherols and Q-tocopherol
Plasma tocopherols were analyzed essentially as described [11].
Brie£y, plasma was isolated from blood (5 ml) drawn into tubes con-
taining EDTA, by centrifugation at 3000 rpm for 10 min at 5‡C and
transferred into plastic tubes. 100-Wl aliquots were stored at 380‡C
under nitrogen until analysis. Previously, we have found that vitamin
E is stable for as long as 2 years under these conditions.
To 100 Wl plasma was added 100 Wl ethanol (ACROS Organics,
Geel, Belgium) and internal standard (K-tocopheryl acetate, 5 Wl,
0.2 mM in ethanol). The sample was vigorously mixed for 10 s and
extracted with 100 Wl n-heptane. Then the n-heptane phase was sepa-
rated and evaporated with nitrogen. The tocopherols converted to
their trimethylsilyl ethers using 50 Wl pyridine p.a. dried (Merck,
Darmstadt, Germany) and 25 Wl N,O-bis(trimethylsilyl)tri£uoroacet-
amide (Fluka, Neu-Ulm, Germany) with 1% trimethylchlorosilane
(Merck, Darmstadt, Germany) in an electrically heated block at
65‡C in closed vials for 15 min.
Derivatized tocopherols were analyzed by GC-MS with a SSQ 710
MAT from Finnigan MAT (Bremen, Germany) with a Varian 3400
Gas Chromatograph. A 30 mU0.25 mm I.D., 0.25-Wm ¢lm thickness
DB-5MS fused-silica column was used for sample separation. The
temperature program was 2 min 180‡C, 10‡C/min to 280‡C and ¢nally
20 min 280‡C. The injector temperature was set to 260‡C and the
transfer line temperature at 300‡C. The carrier gas was helium. The
injection volume was 1 Wl. EI mass spectra were recorded at an ion-
ization energy of 70 eV and an ion source temperature of 150‡C. In
the selected ion-monitoring mode detected masses of the silyl ethers
were as follows: 430 mass units for internal standard K-tocopherol
acetate, 488 mass units for Q-tocopherol and 502 (d0), 505 (d3), 508
(d6) mass units for K-tocopherols. The concentrations of Q-tocopherol,
d0-, d3- and d6-K-tocopherol were calculated from the peak area of
the corresponding molecular ions in the mass spectra relative to the
fragment ion at m/z 430 of the K-tocopheryl acetate internal standard
(molecule ion at m/z 472 is of low intensity). The measurements of d3-
and d6-K-tocopherol were corrected for the contribution of the natu-
ral abundance isotopes (M+3) present in the non-deuterated and d3-
K-tocopherol silyl ether, respectively. Therefore 2.4% of the peak area
of the isotopomer d0-K-tocopherol and d3-K-tocopherol were sub-
tracted from the peak of the isotopomers d3-K-tocopherol and d6-K-
tocopherol, respectively. The results are means of measurement of two
samples of each plasma collection.
2.5. Extraction of the urine samples and measurement of
non-deuterated K- and Q-CEHC and deuterated K-CEHC
Aliquots of 24-h urine collections were lyophilized and the powders
were stored under nitrogen at 380‡C. Three samples of 100 mg were
taken from each urine powder. To one sample 10 Wg (3.6 mM in
ethanol) Trolox (2,5,7,8-tetramethyl-2(2P-carboxymethyl)-6-hydroxy-
chroman, Aldrich, Steinheim, Germany) as internal standard and to
the others 2 Wg Trolox were added. The samples were extracted with
5 ml methanol 3 times and evaporated. Then enzymatic hydrolysis of
the CEHC conjugates was carried out in a mixture of 600 Wl water,
1600 Wl sodium acetate bu¡er (0.1 M, pH 4.5) and 800 Wl enzyme
solution, consisting of 8 mg L-glucuronidase/sulfatase (133 U sulfa-
tase, 2700 U glucuronidase (Sigma G0751, Sigma, Deisenhofen, Ger-
many)) in acetate bu¡er. The tubes were £ushed with argon, closed
and incubated in a shaking water bath at 37‡C for 4 h, then were
extracted 4 times with 5 ml diethylether, and the ether collected and
evaporated under nitrogen. The CEHC compounds were converted to
their silyl ether esters using 100 Wl hexane, 80 Wl N,O-bis(trimethylsi-
lyl)tri£uoroacetamide (Fluka, Neu-Ulm, Germany), 16 Wl N,O-bis(tri-
methylsilyl)acetamide (Aldrich, Steinheim, Germany), 4 Wl trimethyl-
chlorosilane (Merck, Darmstadt, Germany) in an electrically heated
block at 50‡C for 2 h [8,9].
Derivatized deuterated and non-deuterated CEHCs were analyzed
by GC-MS with a SSQ 710 MAT from Finnigan MAT (Bremen,
Germany) with a Varian 3400 Gas Chromatograph. The same
30 mU0.25 mm I.D., 0.25-Wm ¢lm thickness DB-5MS fused-silica
column as for tocopherol analysis was used. The initial temperature
was 100‡C for 0.5 min, followed by an increase of 30‡C/min to 280‡C
and held for 10 min. The injector temperature was 280‡C. The carrier
gas was helium and the transfer line temperature was set at 300‡C.
The injection volume was 2 Wl. Electron ionization mass spectra were
recorded at an ionization energy of 70 eV and an ion source temper-
ature of 150‡C. Selected masses for the silyl ether esters monitored
were: 394 mass units for internal standard Trolox, 408 mass units for
Q-CEHC and 422 (d0), 425 (d3), 428 (d6) mass units for K-CEHC silyl
derivatives. The concentrations of Q-CEHC, d0-, d3- and d6-K-CEHC
were calculated from the peak area of the corresponding molecule
ions relative to the peak area of the molecular ion 394 of the internal
standard Trolox and the response factor. Corrections were made for
the contribution of the naturally silicone isotopes (M+3) present in
the CEHC silyl ether esters di¡ering by three atomic mass units. It
was calculated by subtraction of 2.9% of the peak area of d0-K-CEHC
(m/z 422) from d3-K-CEHC (m/z 425) and of d3-K-CEHC (m/z 425)
from d6-K-CEHC (m/z 428), respectively. The results are means of the
analysis of three samples of each urine collection.
2.6. Statistical analyses
The statistical signi¢cance of the concentrations of the isotopes in
plasma and in the urine was determined using ANOVA with repeated
measures. Comparisons were made using least square means analysis.
Statistical analyses were carried out with SuperAnova (Berkeley, CA,
USA). Results were considered to be signi¢cant at the 95% con¢dence
level (P6 0.05). Reported are the means þ S.E.
3. Results
3.1. Plasma vitamin E concentrations
Measurements of plasma vitamin E concentrations follow-
ing supplementation with natural and synthetic vitamin E
labeled with deuterium were made for the ¢rst 24 h following
dosing. As seen in Fig. 1A, unlabeled plasma K-tocopherol at
time 0 decreased from 23 þ 2 to 21 þ 2 WM (P6 0.009) at 12 h
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Fig. 1. (A) Plasma unlabeled (d0) K- and (B) Q-tocopherols and la-
beled (d3 and d6) K-tocopherols (means þ S.E., n = 6) following ad-
ministration of a single dose containing 150 mg each d3RRR-K- and
d6all rac-K-tocopheryl acetates.
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and to 20 þ 2 WM (P6 0.002) at 24 h. Similarly, plasma Q-
tocopherol decreased from 0.7 þ 0.1 at 0 h to 0.4 þ 0.1 WM
(P6 0.001) at 12 h and to 0.3 þ 0.1 WM (P6 0.0002) at 24 h
(Fig. 1B). Six h after the dose both d3-K- and d6-K-tocopher-
ols attained similar plasma concentrations; however, by 12 h
the concentration of d3-K-tocopherol (4.6 þ 1.2 WM) was sig-
ni¢cantly (P6 0.002) greater than that of d6-K-tocopherol
(2.7 þ 0.7 WM); similar di¡erences were found at 24 h (d3K-
tocopherol (4.1 þ 1.1 WM) vs. d6-K-tocopherol (1.8 þ 0.5 WM,
P6 0.0004) (Fig. 1B).
The ratio of natural to synthetic (d3- to that of d6-K-toco-
pherol) in the plasma increased from approximately 1 in the
administered dose to 1.5 þ 0.1 at 6 h, 1.8 þ 0.1 at 12 h and
2.1 þ 0.1 at 24 h.
3.2. Urinary vitamin E metabolite concentrations
Unlabeled K- and Q-CEHCs were measured in 24-h urine
collections prior to and after deuterated vitamin E dosing. As
shown in Fig. 2, despite the low concentrations of Q-tocopher-
ol in the plasma, the urine contained higher concentrations of
Q-CEHC than of K-CEHC (main e¡ect P6 0.02, daily com-
parisons except on day 2 were statistically signi¢cant,
P6 0.01). Although Q-CEHC was excreted in relatively con-
stant daily amounts, K-CEHC varied in response to the 300
mg of deuterated K-tocopheryl acetate administered. Unla-
beled K-CEHC excretion increased from 1.0 þ 0.2 Wmol on
day 0 to 1.4 þ 0.2 Wmol on day 1 (P6 0.004) to 1.6 þ 0.1
Wmol (P6 0.003) on day 2 and back to 1.3 þ 0.2 Wmol
(P6 0.04) on day 3; subsequent days were not statistically
di¡erent from day 0. Thus, we observed increased unlabeled
K-CEHC excretion in response to deuterated vitamin E sup-
plementation. These data are in accordance with the observa-
tion that new vitamin E replaces the circulating [12,13], and
that excess vitamin E is metabolized [6].
The major purpose of this study was to evaluate excretion
of labeled K-CEHC following administration of d3RRR-K-
and d6all rac-K-tocopheryl acetates. As shown in Fig. 3, me-
tabolites from both forms of vitamin E were readily detected
in urine up to 8 days following dosing. Remarkably, more
d6K-CEHC than d3K-CEHC was excreted daily during the
¢rst 4 days of the study (P6 0.0001 daily, except day 4,
P6 0.0002; day 8, not signi¢cant). This greater excretion of
synthetic vitamin E derived metabolite is more obvious in Fig.
4, where the ratio of metabolite derived from synthetic to
natural vitamin E is shown. The d6/d3 ratio in the adminis-
tered material was 1 and in contrast to the plasma where the
natural vitamin E form was preferentially retained (ratio
equals about 2 in favor of d3RRR-K- compared with d6all
rac-K-tocopherol), in the urine the synthetic was preferentially
excreted. The ratio of synthetic to natural increased from
2.4 on day 1 to 3.3 on day 3 before decreasing back to
1.9 on day 8. The ratio was signi¢cantly greater (P6 0.002)
than the administered dose ratio of 1 on all days.
The total amount of deuterated K-CEHC excreted was esti-
mated by summing the daily values. The total d6-K-CEHC
excreted (1.68 þ 0.30 Wmol) was on average about 2.7 times
that of d3-K-CEHC (0.65 þ 0.12 Wmol, P6 0.002), once again
documenting that more of the d6-all rac-K-tocopherol was
converted to metabolite.
4. Discussion
Synthetic vitamin E (all rac-K-tocopherol), which contains
8 di¡erent stereoisomers resulting from 3 chiral centers in the
phytyl tail, is less biologically potent than the naturally occur-
ring form, RRR-K-tocopherol [14]. Because the K-CEHC me-
tabolite arises from the truncation of the phytyl tail and its
excretion increases in response to ‘excess’ vitamin E, we hy-
pothesized that all rac-K-tocopherol might be metabolized to
K-CEHC more readily than the natural form. By 24 h after
supplementation with 150 mg each d3RRR-K- and d6all rac-K-
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Fig. 2. Urinary unlabeled K- and Q-CEHC (means þ S.E., n = 6) in
24-h urine collections before (0) and following administration of a
single dose containing 150 mg each d3RRR-K- and d6all rac-K-toco-
pheryl acetates.
Fig. 4. Ratio of urinary d3-K- to d6-K-CEHCs (means þ S.E., n = 6)
in 24-h urine collections following administration of a single dose
containing 150 mg each d3RRR-K- and d6all rac-K-tocopheryl ace-
tates.
Fig. 3. Urinary d3-K- and d6-K-CEHC (means þ S.E., n = 6) in 24-h
urine collections following administration of a single dose contain-
ing 150 mg each d3RRR-K- and d6all rac-K-tocopheryl acetates.
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tocopheryl acetates, the plasma ratio of natural to synthetic
(d3 to d6) was about 2, while the opposite was found in the
urine ^ nearly three times as much d6-K-CEHC (derived from
synthetic vitamin E) was excreted!
Increased excretion of the metabolite arising from d6all rac-
K-tocopherol might be a result of the preference of the metab-
olizing system for non-RRR-forms. Or more speci¢cally K-
TTP preferentially sorts out the 2R-forms resulting in the
plasma preference ratio of 2, natural to synthetic. In this
way the liver becomes enriched with the synthetic (2S-forms)
which are then degraded together with excess vitamin E (both
RRR- and other 2R-K-forms, as well as other vitamin E
forms). K-CEHC excretion then re£ects the vitamin E concen-
trations in the liver. Plasma and tissue data reported by Bur-
ton et al. [12] are in accordance with this interpretation.
The lack of change in Q-CEHC excretion in response to
decreases in plasma Q-tocopherol following vitamin E supple-
mentation shown here suggests that Q-CEHC synthesis is
possibly regulated independently of plasma Q-tocopherol
concentrations. Alternatively, the small decreases in plasma
Q-tocopherol result in undetectable increases in Q-CEHC. In
response to deuterated vitamin E supplementation, plasma
unlabeled K- and Q-tocopherol concentrations both decreased
(at least in the ¢rst 24 h after dosing; Fig. 1). Thus, as re-
ported previously, newly absorbed K-tocopherol replaces the
circulating K-tocopherol [12,13], and causes a decrease in cir-
culating Q-tocopherol [15^17]; as shown in Fig. 2, it causes an
increase in K-CEHC excretion [6], but does not further in-
crease Q-CEHC excretion.
The present study was carried out in Germany, where plas-
ma K- to Q-tocopherol ratios were about 20:1, in contrast to
previous reports of subjects studied in the United States who
have K- to Q-tocopherol ratios about 5:1 [18,19]. Despite the
high plasma K- to Q-tocopherol ratio in the present study,
twice as much Q-CEHC compared with K-CEHC was excreted
in the urine. High Q-CEHC excretion levels were also pre-
sented in a preliminary report; Swanson et al. [20] suggested
that all of the Q-tocopherol consumed is converted to Q-
CEHC. Consistent with these observations is the hypothesis
that CEHC metabolites are synthesized from excess liver vi-
tamin E. In the case of Q-tocopherol, little is needed by the
body as evidenced by its rapid turnover [18,21], so Q-CEHC is
readily made from ‘excess’ Q-tocopherol and is increased in
response to increased consumption of Q-tocopherol. Thus,
German subjects have less Q-CEHC in their urine than Amer-
icans because they consume less Q-tocopherol. Following this
logic, less of the synthetic vitamin E is recognized by K-TTP
[5], therefore, like excess Q-tocopherol, less is exported to the
plasma and more synthetic vitamin E is converted to the me-
tabolite.
The lower biological activity of synthetic vitamin E cannot
be quantitatively attributed to its higher rate of metabolism.
Although nearly 3 times as much metabolite was made from
synthetic compared with natural vitamin E, the amounts of
the metabolite produced and excreted in the urine account for
only a few percent of the deuterated vitamin E consumed.
This low level of urinary metabolite excretion is consistent
with the urinary excretion of radioactivity following 3H-K-
tocopherol administration to humans carried out by MacMa-
hon and Neale [22] over 30 years ago. Because only urine was
examined, other routes of CEHC excretion cannot be ruled
out. The amount of CEHC in the bile has not yet been exam-
ined, so the importance of vitamin E metabolism in determin-
ing biological activity and the extent of vitamin E catabolism
to CEHCs remains to be investigated. It is clear that these
metabolites of tocopherols are not oxidation products because
they are derived from unoxidized tocopherols and their syn-
thesis apparently is dependent upon vitamin E being present
in excess. The practical application of CEHC measurements
are not yet clear; potentially they can be used as a measure of
adequacy of vitamin E status, as was suggested by Schultz et
al. [6].
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